32 clinical trials found.
-
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad
If you have been diagnosed with advanced malignancies, an advanced form of cancer, you may be qualified to participate in this Phase I study evaluating ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
If you have been diagnosed with selected advanced or recurrent solid tumors including bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell histology ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)
if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial. The main goal ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer
To evaluate the safety and tolerability of VE800 in combination with nivolumab using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0). To evaluate ...Phase
Interventional
TRIAL ROLE: Sub Investigator
